The present invention relates to a method for the isolation of subpopulations of cardiac progenitor cells from a heart tissue sample, the population thus obtained and the related uses in the medical field for the cell therapy or cardiac cell and/or tissue transplantation field.

The invention provides cellular compositions that contain CD34.sup.+ cells derived from bone marrow of a decease donor and CD3.sup.+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.

The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.

Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.

The present invention concerns a novel human erythroid progenitor cell line, wherein at least 90% of the cells are CD36.sup.+ CD44.sup.?CD71.sup.+; and wherein the cells:do not express the gene encoding the receptor of Granulocyte-macrophage colony-stimulating factor (GM-CSF-R gene) or express GM-CSF-R gene at a lower level than the cells of human UT-7/Epo-S1 cell line; andexpress the gene encoding the receptor of erythropoietin (Epo-R gene). The present invention also concerns the uses thereof for producing, detecting, or quantifying parvovims B19. The present invention allows the use of the cell lines for 1) a highly sensitive B19 infectious particles detection, and, 2) the efficient production of infectious B19 particles.

Provided is a ??T cell for securing the purity and number of cells sufficient for treatment. Also provided is a method of generating the ??T cell. More specifically, provided are homogeneous ??T cells excellent in that the ??T cells are not affected by exhaustion of the cells. The foregoing is achieved by ??T cells obtained by subjecting induced pluripotent stem cells (iPS cells) to differentiation induction treatment. Specifically, the foregoing is achieved by ??T cells generated by subjecting iPS cells having a rearranged ??TCR gene (??TCR-type iPS cells) to differentiation induction treatment. According to the method of generating the ??T cell of the present invention, there can be provided ??T cells and a cell population of ??T cells that have an excellent function of having antigen-specific cytotoxic activity in a MHC-unrestricted manner, and that are more homogeneous and have a higher effect than ??T cells separated from peripheral blood.

A composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and/or tissue transplantation in recipient areas of a subject experiencing cell and/or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and/or immune rejection of a cosmetic cell and/or tissue implant or graft.

Provided are a method for preparing genetically engineered erythrocytes carrying an anti-PD-1 single chain antibody, and genetically engineered erythrocytes carrying the anti-PD-1 single chain antibody. The preparation method comprises the following steps: constructing a desired fragment sequence in a lentiviral expression vector, lentivirally packaging the vector of the desired sequence to obtain a high-titer lentiviral concentrate; isolating Lin.sup.?CD34.sup.? cells from peripheral blood mononuclear cells and enriching the Lin.sup.?CD34.sup.? cells; inducing the Lin.sup.?CD34.sup.? cells to differentiate into erythroid and performing proliferation thereon; using the lentiviral concentrate to infect the Lin.sup.?CD34.sup.? cells; and obtaining mature anti-PD-1 scFv erythrocytes via erythrocyte denucleation. The present genetically engineered erythrocytes carrying the anti-PD-1 single chain antibody can perform the targeted delivery of an anti-PD-1 single-chain antibody to tumor tissues.

Provided is a method of differentiating a pluripotent stem cell-derived hemogenic endothelial cell into a lymphoid lineage blood cell, enabling a hemogenic endothelial cell to be cultured for a long period of time so as to be induced into a lymphoid lineage blood cell, thereby facilitating induction of generation of immune cells such as T cells, B cells, and NK cells.